普萊柯(603566.SH):子公司獲得新獸藥註冊證書
格隆匯4月11日丨普萊柯(603566.SH)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,經農業農村部審查,批准全資子公司洛陽惠中獸藥有限公司(以下簡稱“惠中獸藥”)與濟南領派生物醫藥科技有限公司等單位聯合申報的“青黴素V鉀可溶性粉”為新獸藥,並於2025年4月10日公示了核發《新獸藥註冊證書》(中華人民共和國農業農村部公吿第899號)事項。該新獸藥為子公司惠中獸藥與濟南領派生物醫藥科技有限公司等單位聯合開發,農業農村部於2025年4月10日公吿核發新獸藥註冊證書。
青黴素V鉀可溶性粉用於治療由梭狀芽胞桿菌引起的雞壞死性腸炎,國外已臨牀應用多年,具有安全性、高效性(胃酸穩定,高生物利用度)、臨牀使用便捷性的優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.